Furthermore, the authors propose that co-administration of PLGA NPs with either an MHC class I or an additional MHC class II restricted epitope along with both TLR ligands induced almost complete blockage of tumor growth, suggesting the important activation of both CD8+ and CD4+ T cell responses for efficacy of anti-tumor immunity. Here, CD4 is linked to neoplasm.